Medidata, a global provider of creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that Medpace Inc. has entered into an agreement to integrate Medidata Rave Imaging with Medpace's imaging systems and workflow. This will create a platform for capturing, managing, analyzing and storing images and imaging data for clinical trials. Medpace is a contract research organization (CRO) with a wholly owned and fully integrated imaging core lab that offers a suite of global imaging services to enhance and expedite biopharmaceutical and medical device development.
Glen de Vries, co-founder and co-CEO of Medidata, said, “As drug and medical device development depend more on medical imaging, it’s more important than ever to simplify and unify image and data collection. This helps to minimize risk and complexity, and ensures accurate, rapid completion of clinical studies so patients can more quickly benefit from new therapeutics.”
The use and importance of medical imaging in clinical studies continues to grow. Today, over 50 percent of all studies use medical imaging to help determine the efficacy of new drugs and devices and 95 percent when it is an oncology study. Medidata Rave Imaging is an end-to-end cloud-based platform for image management in clinical trials. This includes image capture, advanced edit checks, workflow, form design, electronic data capture (EDC) connection, and intelligent archiving. Medidata processes more than 500 million images annually from nearly 800 studies.
Using Medidata Rave Imaging, Medpace’s imaging core lab will:
“Through our partnership with Medidata, Medpace is now able to provide integration of our quantitative image analysis pipelines with Medidata’s Rave Imaging system and database,” said Daniel O’Leary, MD, chief medical officer for Medpace’s imaging core lab.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.